IP Library Granted Patent US 6,838,093
Granted Patent B2
US 6,838,093 · App. 09/872,173 · Granted Jan 4, 2005

System for osmotic delivery of pharmaceutically active agents

Assignee: Shire Laboratories, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,838,093
App. No.
09/872,173
Granted
Jan 4, 2005
Kind
B2
Abstract

An osmotic system for delivering a pharmaceutically active agent which comprises a core portion, a layer portion enclosing the core portion, and a semipermeable wall portion enclosing the core portion and the layer portion. The core portion includes the pharmaceutically active agent at a first concentration. The pharmaceutically active agent is present in the layer portion at a second concentration. The second concentration is greater than the first concentration. Such a system provides for the osmotic release of the pharmaceutically active agent in release profile other than a zero order release profile, and wherein the release profile is similar to or approaches or reaches a first order release profile.

Claims (27)

1. An osmotic system for delivering a pharmaceutically active agent, comprising:

a core portion, wherein said core portion includes said pharmaceutically active agent at a first concentration;

a layer portion enclosing and directly adjacent to said core portion, wherein said layer portion includes said pharmaceutically active agent at a second concentration, said second concentration being greater than said first concentration; and

a semipermeable wall portion enclosing said core portion and said layer portion.

2. The system of claim 1 wherein said pharmaceutically active agent is a protein or peptide.

3. The system of claim 1 wherein said semipermeable wall portion is formed from cellulose acetate.

4. The system of claim 1 wherein said pharmaceutically active agent is present in said portion in an amount of about 60 wt. %.

5. The system of claim 1 wherein said pharmaceutically active agent is present in said layer portion in an amount of about 90 wt. %.

6. The system of claim 1 wherein said pharmaceutically active agent is pseudoephedrine or its salts.

7. An osmotic system for delivering a first pharmaceutically active agent and a second pharmaceutically active agent, comprising:

a core portion, wherein said core portion includes said first pharmaceutically active agent at a first concentration;

a first layer portion enclosing and directly adjacent to said core portion, wherein said layer portion includes said first pharmaceutically active agent at a second concentration, said second concentration being greater than said first concentration;

a semipermeable wall portion enclosing said core portion and said first layer portion; and

a second layer portion including a second pharmaceutically active agent, said second layer enclosing said semipermeable wall portion.

8. The system of claim 7 wherein said first pharmaceutically active agent is present in said core portion in an amount of about 60 wt. %.

9. The system of claim 7 wherein said first pharmaceutically active agent is present in said first layer portion in an amount of about 90 wt. %.

10. The system of claim 7 wherein said second pharmaceutically active agent is present in said second layer portion in an amount of from about 2 wt. % to about 99 wt. %.

11. The system of claim 10 wherein said second pharmaceutically active agent is present in said second layer portion in an amount of from about 60 wt. % to about 95 wt. %.

12. The osmotic system of claim 1 , wherein said pharmaceutically active agent is an antitussive, antihistamine, expectorant or decongestant.

13. The osmotic system of claim 12 , wherein said pharmaceutically active agent is chlorpheneramine or its salts, diphenhydramine, or dimenhydramine.

14. The osmotic system of claim 1 , wherein said pharmaceutically active agent is cyctosporin, carmustine, carbamazepine, desmopreson, dihydroergotamine, fluorouracil, heparin sodium, ribavirin, sumitriptan succinate, flutamide, naltrexone HCl, terbutaline sulfate, triamterene, terazosin, parazosin, nifedipine, calcitonin, parathyroid hormone, or GLP-1.

15. The osmotic system of claim 7 , wherein said first pharmaceutically active agent is an antitussive, antihistamine, expectorant or decongestant.

16. The osmotic system of claim 15 , wherein said first pharmaceutically active agent is chlorpheneramine or its salts, diphenhydramine, or dimenhydramine.

17. The osmotic system of claim 15 , wherein said first pharmaceutically active agent is pseudoephedrine or its salts.

18. The osmotic system of claim 7 , wherein said first pharmaceutically active agent is cyclosporin, carmustine, carbamazepine, desmopreson, dihydroergotamine, fluorouracil, heparin sodium, ribavirin, sumitriptan succinate, flutamide, naltrexone HCl, terbutaline sulfate, triamterene, calcitonin, insulin, parathyroid hormone, or GLP-1.

19. The osmotic system of claim 15 , wherein said second pharmaceutically active agent is loratidine, desloratidine, astemizole, norastemizole or ebastine.

20. The osmotic system of claim 7 , wherein said first pharmaceutically active agent is pseudoephedrine or its salts, and said second pharmaceutically active agent is loratidine.

Assignments (17)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0795 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055846/0246 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055845/0618 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2017
From: U.S. BANK NATIONAL ASSOCIATION
To: SUPERNUS PHARMACEUTICALS, INC.
Reel/Frame 044552/0694 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ENDO PHARMACEUTICALS, INC.; ENDO PHARMACEUTICALS SOLUTIONS, INC.; ASTORA WOMEN'S HEALTH HOLDINGS, LLC
Reel/Frame 042362/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF RECEIVING PARTY IN RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS PREVIOUSLY RECORDED ON REEL 032380 FRAME 0157. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS.. Recorded Mar 24, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 032513/0255 →
GRANT OF SECURITY INTEREST IN LICENSED PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0620 →
RELEASE OF PATENT SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS SOLUTIONS INC.
Reel/Frame 032380/0157 →
SECURITY AGREEMENT Recorded Jun 7, 2013
From: SUPERNUS PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 030571/0679 →
RELEASE OF SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS RECORDED AT REEL/FRAME 25456/172 Recorded Jul 12, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 026577/0357 →
SECURITY INTEREST IN EXCLUSIVELY LICENSED PATENTS Recorded Jul 8, 2011
From: ENDO PHARMACEUTICALS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026561/0978 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 23928/628 Recorded Dec 9, 2010
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 025456/0778 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS) Recorded Dec 9, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025456/0172 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (EXCLUSIVELY LICENSED PATENTS) Recorded Feb 13, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 023928/0628 →
LICENSE Recorded Dec 11, 2009
From: SHIRE LABORATORIES INC.
To: ENDO PHARMACEUTICALS SOLUTIONS INC. FORMERLY INDEVUS PHARMACEUTICALS INC.
Reel/Frame 023639/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2006
From: SHIRE LABORATORIES, INC
To: SUPERNUS PHARMACEUTICALS, INC
Reel/Frame 017596/0304 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2001
From: BURNSIDE, BETH A.; FLANNER, HENRY H.; MCKNIGHT, LISA C.
To: SHIRE LABORATORIES, INC.
Reel/Frame 012208/0930 →
Continuity (1)
Related Publication 20030003150A1 · Jan 2, 2003